228 related articles for article (PubMed ID: 15868915)
1. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
Yamaguchi Y; Hironaka K; Okawaki M; Okita R; Matsuura K; Ohshita A; Toge T
Anticancer Res; 2005; 25(2A):827-32. PubMed ID: 15868915
[TBL] [Abstract][Full Text] [Related]
2. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
[TBL] [Abstract][Full Text] [Related]
3. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
[TBL] [Abstract][Full Text] [Related]
4. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
Suzuki E; Niwa R; Saji S; Muta M; Hirose M; Iida S; Shiotsu Y; Satoh M; Shitara K; Kondo M; Toi M
Clin Cancer Res; 2007 Mar; 13(6):1875-82. PubMed ID: 17363544
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies.
Okita R; Yamaguchi Y; Emi A; Matsuura K; Toge T
Oncol Rep; 2007 Jun; 17(6):1429-35. PubMed ID: 17487401
[TBL] [Abstract][Full Text] [Related]
6. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.
zum Büschenfelde CM; Hermann C; Schmidt B; Peschel C; Bernhard H
Cancer Res; 2002 Apr; 62(8):2244-7. PubMed ID: 11956077
[TBL] [Abstract][Full Text] [Related]
7. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
8. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
Varchetta S; Gibelli N; Oliviero B; Nardini E; Gennari R; Gatti G; Silva LS; Villani L; Tagliabue E; Ménard S; Costa A; Fagnoni FF
Cancer Res; 2007 Dec; 67(24):11991-9. PubMed ID: 18089830
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma.
Tong AW; Lee JC; Wang RM; Ordonez G; Stone MJ
Cancer Res; 1989 Aug; 49(15):4103-8. PubMed ID: 2545333
[TBL] [Abstract][Full Text] [Related]
10. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
Mittendorf EA; Storrer CE; Shriver CD; Ponniah S; Peoples GE
Ann Surg Oncol; 2006 Aug; 13(8):1085-98. PubMed ID: 16865596
[TBL] [Abstract][Full Text] [Related]
11. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
12. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
13. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
14. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
15. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
16. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
[TBL] [Abstract][Full Text] [Related]
18. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
[TBL] [Abstract][Full Text] [Related]
19. [The anti-pancreatic cancer efficacy of LAK cells mediated by YPC3 monoclonal antibody in vitro and in vivo].
Chen QK; Yuan SZ
Zhonghua Zhong Liu Za Zhi; 1994 Sep; 16(5):353-5. PubMed ID: 7895586
[TBL] [Abstract][Full Text] [Related]
20. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
Ting CC; Hargrove ME; Yun YS
J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
